Vectivbio price target raised to $25 from $23 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Vectivbio to $25 from $23 and keeps an Overweight rating on the shares after taking over coverage of the name. The analyst continues to recommend the shares after the Q4 report. Timelines remain on track for the company’s lead asset apraglutide, the analyst tells investors in a research note.